The short version of Deamidation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, conformation, and the surrounding matrix. In the solid state, lyophilized powders are generally more stable than solutions because low water activity slows hydrolysis and oxidation. Residual moisture, oxygen, trace metals, and light can still promote degradation over time. Storage recommendations therefore balance temperature, humidity, and container integrity rather than relying on a single condition. The optimal condition for a given peptide is often determined empirically because no universal rule covers every sequence.
In aqueous solution, peptides are vulnerable to hydrolysis, oxidation, deamidation, and aggregation, with rates influenced by pH, temperature, buffer composition, and ionic strength. Acidic or neutral pH ranges often slow deamidation, while extreme pH can accelerate peptide bond cleavage. Dissolved oxygen and redox-active metal ions contribute to oxidation of methionine, cysteine, and tryptophan residues. Aggregation may be driven by hydrophobic interactions or by interfaces such as air-liquid and container surfaces. Because these pathways interact, solution storage usually requires tighter control than storage of dried material.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid; may appear fluffy or crystalline |
| Solubility class | Water-soluble or sparingly soluble | Depends on sequence and counter-ion content |
| Typical storage temperature | -20 °C or lower for solids | Refrigeration may suffice for short-term use |
| Common analytical method | Reverse-phase HPLC | Purity and degradation products are often assessed by UV detection |
| Primary stability risks | Moisture, oxygen, light, heat | Aggregation and hydrolysis can also occur in solution |
Moisture, oxygen, and light also affect peptide integrity. Lyophilized powders absorb water from the air, which can enable hydrolysis and conformational changes. Oxygen promotes oxidation of sensitive residues, so storage under inert gas or in sealed vials is common. Light exposure can cause photodegradation, particularly for peptides containing aromatic amino acids. Buffer choice and pH influence charge state and solubility; extremes of pH accelerate deamidation and hydrolysis. Adding stabilizers such as sugars or polyols can protect the peptide during freezing and drying. Optimal conditions are determined empirically for each peptide.
Peptides are short chains of amino acids that can undergo both chemical and physical degradation. Chemical pathways include hydrolysis of peptide bonds, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and isomerization of aspartate. Physical instability leads to aggregation, precipitation, or adsorption to surfaces. The rate of these processes depends on the peptide sequence, the formulation, and the storage environment. Because each peptide has a unique composition, no single storage condition applies to all peptides. Stability studies are therefore conducted to define suitable conditions for each specific molecule.
Temperature is a primary factor in peptide storage. Lower temperatures reduce molecular motion and slow degradation reactions, but freezing can concentrate solutes and promote aggregation. Lyophilized powders are commonly held at -20°C, whereas solutions are often kept at -80°C. Repeated freeze-thaw cycles are harmful because ice crystal formation and pH shifts can damage the peptide. The glass transition temperature of a lyophilized cake influences its stability; below this temperature, molecular mobility is restricted. For solutions, the choice between -20°C and -80°C depends on the peptide's sensitivity and the intended storage duration.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
=== Regulatory flexibility === Emergency regulatory pathways created during the pandemic demonstrated the potential for more flexible oversight frameworks. The FDA's Emergency Use Authorizations for COVID-19 tests expanded point-of-care and over-the-counter testing options, establishing precedents that may influence future regulatory approaches for other diagnostic tests.
A methadone clinic is a medical facility where medications for opioid use disorder (MOUD) are dispensed. Historically and most commonly, these MOUDs are methadone, although buprenorphine is also increasingly prescribed. Medically assisted drug therapy treatment is indicated in patients who are opioid-dependent or have a history of opioid dependence. Methadone is a schedule II (USA) opioid analgesic, that is also prescribed for pain management. It is a long-acting opioid that can delay the opioid withdrawal symptoms that patients experience from taking short-acting opioids, like heroin, and allow time for withdrawal management. In the United States, by law, patients must receive methadone under the supervision of a physician, and dispensed through the Opioid Treatment Program (OTP) certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) and registered with the Drug Enforcement Administration (DEA). The usual process at the clinic is dispensing methadone daily in liquid form, and ingestion is supervised by the physician. Initially, methadone treatment consists of 30mg to 40mg of methadone. Initial doses are followed by increases in the following days until withdrawal symptoms are suppressed. Many patients with opioid use disorder see effective results in symptom management and compliance on 80mg to 120mg of methadone per day. Although there is no set schedule for the gradual increase of dosage, patients typically experience a 5mg to 10mg increase each day for 5-7 days, until they are maintaining a 60mg per day dosage under physician observation.
Testosterone is metabolized primarily in the liver mainly (90%) by reduction via 5α- and 5β-reductase and conjugation via glucuronidation and sulfation. The major urinary metabolites of testosterone are androsterone glucuronide and etiocholanolone glucuronide. The elimination half-life of testosterone varies depending on the route of administration and formulation and on whether or not it is esterified. The elimination half-life of testosterone in the blood or by intravenous injection is only about 10 minutes. Conversely, testosterone and testosterone esters in oil solution or crystalline aqueous suspension administered by intramuscular or subcutaneous injection have much longer half-lives, in the range of days to months, due to slow release from the injection site.
Following comprehensive lifestyle modifications, the average maintained weight loss is more than 3 kg (6.6 lb) or 3% of total body mass, and could be sustained for five years, and up to 20% of the individuals maintain a weight loss of at least 10% (average of 33 kg). There is some evidence that fast weight loss produce greater long-term weight loss than gradual weight loss. Moderate on-site comprehensive lifestyle changes produce a greater weight loss than usual care, of 2 to 4 kg on average in 6 to 12 months. High-intensity comprehensive programs usually yield more weight loss than moderate or low-intensity, with about 35% to 60% of overweight individuals maintaining more than 5 kg weight loss after 2 years. The NICE devised a set of essential criteria to be met by commercial weight management organizations to be approved. The Transtheoretical Model (TTM) has been used as a framework to assist the design of lifestyle modification programmes, including weight management. A systematic review found that there is insufficient evidence to draw conclusions regarding the effects of TTM-based programs targeting weight loss that included dietary or physical activity interventions, or both (and also combined with other interventions), on sustainable weight loss (one year or longer) in overweight and obese adults. However, very low quality evidence points that this approach may induce positive changes in physical activity and dietary habits, such as increased in exercise duration and frequency, improvement in fruits and vegetables consumption, and reduced dietary fat intake.
Sources: en.wikipedia.org
Unnamed sources told the Miami Herald that, in the call, Trump offered safe passage for Maduro and his immediate family, but the discussion stalled because Maduro would not agree to leave quickly, wanted "global amnesty for any crimes he and his group had committed", and wanted to retain control over Venezuela's military. By mid-December, the US had moved more specialized military assets to Puerto Rico and the Dominican Republic that would support targeted land strikes, seizures of oil tankers or enforcement of an oil embargo. The 158th Fighter Wing of the Vermont Air National Guard deployed to Puerto Rico in December with F-35As. After a week in which more personnel and assets were deployed to the region, including special operations units "trained to support high-risk infiltration and extraction missions", on 22 December, referring to the military buildup, Trump stated: "Soon we will be starting the same program on land." In late December, the first land strike in Venezuela was on a port facility that the US alleged was used by drug traffickers. On 3 January 2026, explosions and low-flying aircraft were reported in Caracas and other locations and Maduro was captured in Operation Absolute Resolve by the US.
== Medicinal Chemistry career == While at Merck & Co., where he was hired as a researcher in 1950, he led a team that developed a method to synthesize the enzyme ribonuclease. His team was successful, with their results announced in January 1969 parallel with those from a separate team led by Bernd Gutte and Robert Bruce Merrifield at Rockefeller University who also achieved synthesis of the same enzyme using a different method. The comparatively simple 124-amino acid structure of ribonuclease made it a logical target for the first enzyme to synthesize. Hirschmann's team built the enzyme in amino acid groups from six to 17 in length which were assembled into two large sections that were linked together, while Merrifield's approach was to assemble the entire enzyme by linking one amino acid at a time at the end of a chain. The achievement was front-page news in The New York Times, heralding the fact that "An Enzyme Is Synthesized for First Time" and providing coverage of a joint announcement by the two teams. While no immediate applications were foreseen, the Merck team noted that the ability to synthesize enzymes opened a new class of drugs for potential therapeutic use. In Hirschmann's obituary in The New York Times, chemist Daniel Rich described the feat of synthesizing an enzyme as "a huge discovery" that "bridged the interface between chemistry and biology", and that by the time of Hirschmann's death the accomplishment was "just routine".
==== Ireland ==== In Ireland, new regulations came into effect on 1 August 2010 concerning codeine, due to worries about the overuse of the drug. Codeine remains a semi non-prescriptive, over-the-counter drug up to a limit of 12.8 mg per pill, but codeine products must be out of the view of the public to facilitate the legislative requirement that these products "are not accessible to the public for self-selection". In practice, this means customers must ask pharmacists for the product containing codeine in name, and the pharmacist makes a judgement whether it is suitable for the patient to be using codeine, and that patients are fully advised of the correct use of these products. Products containing more than 12.8 mg codeine are available on prescription only.
However, Fewster, who had a flourishing variolation practice, may have considered this option but used smallpox instead. He thought vaccination offered no advantage over variolation, but maintained friendly contact with Jenner and certainly made no claim of priority for vaccination when critics attacked Jenner's reputation. It seems clear that the idea of using cowpox instead of smallpox for inoculation was considered, and actually tried in the late 18th century, and not just by the medical profession. Therefore, Jenner was not the first to try cowpox inoculation. However, he was the first to publish his evidence and distribute vaccine freely, provide information on selection of suitable material, and maintain it by arm-to-arm transfer. The authors of the official World Health Organization (WHO) account Smallpox and its Eradication assessing Jenner's role wrote:
== Synthesis and structure == With the formula Zn[(S2P(OR)2]2, zinc dithiophosphate features diverse R groups. Typically, R is a branched or linear alkyl between 1-14 carbons in length. Examples include 2-butyl, pentyl, hexyl, 1,3-dimethylbutyl, heptyl, octyl, isooctyl (2-ethylhexyl), 6-methylheptyl, 1-methylpropyl, dodecylphenyl, and others. A list of examples with their CAS numbers is here. Zinc dithiophosphate are often produced in two steps. First phosphorus pentasulfide is heated with suitable alcohols (ROH) to give the dithiophosphoric acid. A wide variety of alcohols can be employed, which allows the lipophilicity of the final zinc product to be fine tuned. The resulting dithiophosphoric acid is then neutralized, e.g., with ammonia or by adding zinc oxide:
Sources: en.wikipedia.org
Colonial: small, regular groups of motile cells Capsoid: individual non-motile cells embedded in mucilage Coccoid: individual non-motile cells with cell walls Palmelloid: nonmotile cells embedded in mucilage Filamentous: a string of connected nonmotile cells, sometimes branching Parenchymatous: cells forming a thallus with partial differentiation of tissues In three lines, even higher levels of organization have been reached, with full tissue differentiation. These are the brown algae,—some of which may reach 50 m in length (kelps)—the red algae, and the green algae. The most complex forms are found among the charophyte algae (see Charales and Charophyta), in a lineage that eventually led to the higher land plants. The innovation that defines these nonalgal plants is the presence of female reproductive organs with protective cell layers that protect the zygote and developing embryo. Hence, the land plants are referred to as the Embryophytes.
Mentha × piperita 'Candymint' has reddish stems. Mentha × piperita 'Chocolate Mint'. Its flowers open from the bottom up; its flavour is reminiscent of the flavour in Andes Chocolate Mints, a popular confection. Mentha × piperita 'Citrata' includes a number of varieties including Eau de Cologne mint, grapefruit mint, lemon mint, and orange mint. Its leaves are aromatic and hairless. Mentha × piperita 'Crispa' has wrinkled leaves. Mentha × piperita 'Lavender Mint' Mentha × piperita 'Lime Mint' has lime-scented foliage. Mentha × piperita 'Variegata' has mottled green and pale yellow leaves. Commercial cultivars may include:
Dutasteride, sold under the brand name Avodart among others, is a medication primarily used to treat the symptoms of a benign prostatic hyperplasia (BPH), an enlarged prostate not associated with cancer. It is also used to treat pattern hair loss in men as an off-label medication and as an approved medication in South Korea, Japan, and Taiwan. A few months may be required before benefits occur. It is usually taken by mouth; however, topical versions exist for those with hair loss, which are designed to minimize systemic exposure by acting specifically on hair follicles. The most commonly reported side effects of dutasteride, although rare, include sexual dysfunction. In the largest available study of 6,729 men with BPH, 9% experienced erectile dysfunction (compared to 5.7% treated with a placebo), 3.3% experienced decreased sex drive (vs 1.6% of placebo), and 1.9% had enlarged breasts (vs 1% of placebo). Exposure during pregnancy is specifically contraindicated because antiandrogens such as dutasteride have been shown to interfere with the sexual development of male fetuses. Dutasteride was patented in 1993 by Glaxo Wellcome (later known as GSK after additional mergers) and was approved for medical use in 2001. It is available as a generic medication and as such, manufactured and exported more by India than elsewhere. In 2023, it was the 236th most commonly prescribed medication in the US with more than 1 million prescriptions.
Castor oil has been used in cosmetic products, included in creams, and used as a moisturizer. It is often combined with zinc oxide to form an emollient and astringent, zinc and castor oil cream, which is commonly used to treat infants for nappy rash. Hydrogenated castor oil is also known as trihydroxystearin, which is used in cosmetics and personal care systems.
In November 1997 National Theatre of Greece launched a worldwide tour of Medea, a critically acclaimed production directed by Nikaiti Kontouri, starring Karyofyllia Karambeti as Medea, Kostas Triantafyllopoulos as Creon and Lazaros Georgakopoulos as Jason. The tour included performances in France, Australia, Israel, Portugal, United States, Canada, Turkey, Bulgaria, China and Japan and lasted almost two years, until July 1999. The play opened in the United States at Shubert Theatre in Boston (18 and 19 September 1998) and then continued at City Center Theatre in Manhattan, New York City (23 to 27 September 1998), receiving a very positive review from The New York Times. Neil LaBute wrote Medea Redux, a modern retelling, first performed in 1999 starring Calista Flockhart, as part of his one-act trilogy entitled Bash: Latter-Day Plays. In this version, the main character is seduced by her middle-school teacher. He abandons her, and she kills their child out of revenge. Michael John LaChiusa created a Broadway musical adaptation work for Audra McDonald entitled Marie Christine in 1999. McDonald portrayed the title role, and the show was set in 1890s New Orleans and Chicago. Liz Lochhead's Medea previewed at the Old Fruitmarket, Glasgow as part of Theatre Babel's Greeks in 2000 before the Edinburgh Fringe and national tour. "What Lochhead does is to recast MEDEA as an episode-ancient but new, cosmic yet agonisingly familiar- in a sex war which is recognisable to every woman, and most of the men, in the theatre", wrote The Scotsman.
Sources: en.wikipedia.org
Lyophilized peptides have low water activity, which slows hydrolysis and many oxidative pathways. Low temperatures further reduce residual chemical reactivity and microbial growth risk. The exact temperature depends on peptide stability data and expected storage duration.
Common pathways include hydrolysis, oxidation, deamidation, and aggregation. Their rates depend on pH, moisture, oxygen, trace metals, light, and temperature. Container surfaces and air-liquid interfaces can also promote loss or structural change.
No. Freezing can concentrate salts and buffer species, cause pH shifts, and damage peptides during ice crystal formation. Repeated freeze-thaw cycles are particularly disruptive. Refrigeration or single-use aliquots may be preferable for some solutions.
Aliquoting divides a stock into portions that can be thawed once and used without returning the whole batch to storage. This limits temperature cycling and reduces the chance of contamination or concentration changes. It also makes it easier to track how many portions remain.